Episode 61

Precision Pioneers EP 5: Alnylam's Josh Friedman on developing precision medicines for the 'silent killer' NASH/NAFLD

00:00:00
/
00:34:28

May 5th, 2021

34 mins 28 secs

Your Host

About this Episode

On this episode of the podcast, Patrick is joined by Josh Friedman, Senior Director of Research at Alnylam Pharmaceuticals. Alnylam works on the discovery and development of RNA interference therapeutics; treatments for genetic diseases which work by ‘switching off’ the specific genes associated with a given condition. In this fifth episode of our precision pioneers miniseries, we explore how RNA interference can be applied to treat common and rare genetic diseases, and dive deep into the genetics of non-alcoholic fatty liver disease and NASH.